Getting better value from the NHS drug budget

BMJ

Volumn 342, Issue 7787, 2011, Pages 30-31

  Moon, James C ^a   Flett, Andrew S ^a   Godman, Brian B ^b,c   Grosso, Anthony M ^a   Wierzbicki, Anthony S ^d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CANDESARTAN; CITALOPRAM; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; ESCITALOPRAM; ESOMEPRAZOLE; GENERIC DRUG; IRBESARTAN; LOSARTAN; OLMESARTAN; OMEPRAZOLE; SIMVASTATIN; TELMISARTAN; VALSARTAN;

ARTICLE; BUDGET; COCHRANE LIBRARY; DRUG DOSE INCREASE; DRUG INDUSTRY; DRUG MEGADOSE; HEALTH CARE COST; HEART FAILURE; HUMAN; HYPERTENSION; NATIONAL HEALTH SERVICE; PRIORITY JOURNAL;

EID: 78650786004     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6449     Document Type: Article

References (21)

1. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8:7-24.
2. NHS Information Centre. Prescription cost analysis 2009, 2010.
3. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it. Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008;26:91-8.
4. Light DW. The risks of prescription drugs. Columbia University Press, 2010.
5. Moon JC, Bogle RG. Switching statins. BMJ 2006;332:1344-5.
6. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62:480-4. (Pubitemid 351197428)
7. Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008;26:537-50. (Pubitemid 351871549)
8. Universtiy College London Hospital NHS Trust. UCLH guidelines on angiotensin II receptor blockers (ARBs) for hypertension and heart failure. UCLH, 2010. www.uclh.nhs.uk/NR/rdonlyres/408E7244-DCF1-4742-AAE1-9B16455C69B6/0/ UCLHARBGUIDELINESFINAL.pdf.
9. Godman B, Bucsics A, Burkhardt T, Schmitzer M, Wettermark B, Wieninger P. Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2010;10:199-207.
10. Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev 2008;4:CD003822.
11. British Hypertension Society. Guidelines for the management of hypertension. BHS, 2010.
12. Meredith P. Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. J Hum Hypertens 2009;24:525-31.
13. Kjeldsen SE, Stalhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010;24:263-73.
14. Erhardt LR. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. Int J Clin Pract 2005;59:571-8.
15. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374:1840-8.
16. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010;10:73-85.
17. Godman B, Shrank W, Wettermark B, Andersen M, Bishop I, Burkhardt T, et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 2010;3:2470-94.
18. Godman B, Burkhardt T, Bucsics A, Wettermark B, Wieninger P. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future. Expert Rev Pharmacoecon Outcomes Res 2009;9:475-84.
19. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. (Pubitemid 47404299)
20. Gumbs PD, Verschuren WM, Souverein PC, Mantel-Teeuwisse AK, de Wit GA, de Boer A, et al. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. Br J Clin Pharmacol 2007;64:680-5.
21. Prosser H, Walley T. A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing. Soc Sci Med 2005;60:1335-46. (Pubitemid 40038762)